Key result
Alere point-of-care analyzer shows high agreement with reference lab for metabolic syndrome markers.
Why the study?
Do point-of-care blood analyzers in a mobile setup provide reliable and valid metabolic syndrome diagnosis compared to a reference laboratory in adult participants?
Observational (n=50)
Do point-of-care blood analyzers in a mobile setup provide reliable and valid metabolic syndrome diagnosis compared to a reference laboratory in adult participants?
A mobile setup using the Alere POC analyzer provides valid and reliable screening for metabolic syndrome risk factors compared to standard laboratory testing.
Background The metabolic syndrome (MetS) is characterized by having three or more of these risk factors: increased blood glucose (Glc), serum triglycerides (TG), blood pressure (BP), waist circumference (WC), and reduced high-density lipoprotein (HDL). Mobile diagnostics using point-of-care (POC) blood analyzers could help identify individuals at risk. This pilot study assessed reliability and validity of MetS risk factor analysis using POC analyzers in a mobile examination unit. Methods Fifty participants (52 ± 7y; 170 ± 10 cm; 80 ± 19 kg, m/f: 21/29) were included for analysis. The mobile examination unit was equipped with different POC analyzers (Alere, LABGEO, CardioChek for Glc, HDL, TG; Quo-Test-A1C Testkit for HbA1c‘). Agreement compared to a reference laboratory (RefLab) was analyzed by Bland-Altman (bias, Limits of Agreement (LoA)), ICC, SEM and McNemar’s test. Test-retest analysis was assessed on two different days (max. two weeks apart) using Spearman’s rho, ICC, test-retest variability (TRV%) and McNemar’s test. Results Based on the smallest bias and low number of missing values (Glc: -5 [LoA − 25 to 6] mg/dl; TG: 8 [LoA − 58 to 30] mg/dl; HDL: -2 [LoA − 14 to 9] mg/dl), and the highest agreement in MetS diagnosis compared to the results of RefLab, the Alere POC device was chosen. Test-retest reliability ( n = 16) for MetS risk factors and HbA1c measured in the mobile setup ranged from poor to excellent with low TRV (0.9–5.8%). Risk factor classification and MetS diagnosis did not differ between measurement days. Conclusions A mobile setup using the Alere POC analyzer could be used as a valid mobile screening method for MetS to ensure early detection of risk factors.
No takes yet. Share an insight, caveat, or question.
Houtenbos et al. (2026) conducted an observational in Metabolic syndrome (n=50). Point-of-care (POC) blood analyzers vs. Reference laboratory was evaluated on Agreement with reference laboratory (bias and Limits of Agreement). The Alere point-of-care analyzer demonstrated high agreement with a reference laboratory for metabolic syndrome risk factors, with small biases for glucose (-5 mg/dl), triglycerides (8 mg/dl), and HDL (-2 mg/dl).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: